Medical Necessity Assessment for Home Factor VIII Supply in Hemophilia A

Rationale for Medical Necessity

• The Haematologica international guidelines establish that Factor VIII concentrates are indicated for congenital hemophilia A patients, particularly for on-demand treatment of bleeding episodes, with a low inhibitor titer (0.1 BU/mL) making Factor VIII replacement appropriate 1
• The patient meets the MCG criteria, including confirmed congenital Factor VIII deficiency (hemophilia A) with documented levels, favorable response to prior Factor VIII administration, and antibody inhibitor screening completed with low titer (0.1 BU/mL, well below 10 BU/mL threshold) 1
• Delays in Factor VIII administration for acute bleeding episodes, particularly intracranial or major joint bleeds, significantly increase morbidity and mortality risk, making home availability of Factor VIII critical for optimal outcomes 1